2016 To investigate tumour characteristics, treatments, and survival of urinary bladder cancer with respect to genderrelated differences.
Female gender had shorter cancer-specific and relative survival, higher rate of aggressive tumours and lower probability of receiving optimal treatment, compared to male gender. Jahnson et al. [2] 2015 To investigate temporal trends over 15 years in tumour characteristics, management and survival in bladder cancer
Increasing age of the patients at diagnosis, decreasing proportion of muscle-invasive tumours, more aggressive treatment but no changes in relative survival over time. Liedberg et al. [3] 2015 To investigate recurrence and progression of non-muscle invasive bladder cancer (NMIBC)
High rate of recurrence and progression, and important disparities in outcome exist between healthcare regions. Patschan et al. [4] 2015 To investigate the use of Bacillus Calmette-Guérin (BCG) in stage T1 bladder cancer Intravesical BCG is underused in stage T1 bladder cancer, particularly in patients 75 years or older, and in those treated at lowvolume hospitals. Jerlström et al. [5] 2014 To evaluate complications within 90 days after radical cystectomy.
Higher risk of complications in patients with longer operating time and higher age.
Sabir et al. [6] 2013 To evaluate the impact of hospital volume on local recurrence and distant metastasis after radical cystectomy Local tumour recurrence after cystectomy was common and more frequent at low volume hospitals than high volume hospitals. Furthermore, overall survival was better at high volume hospitals. Liedberg et al. [7] 2012 To evaluate complications and reoperations after radical cystectomy for primary bladder cancer
Radical cystectomy was associated with a reoperation rate of 24%, with higher rates in patients receiving a continent cutaneous diversion or bladder substitution. Jahnson et al. [8] 2010 To investigate the type of urinary diversion performed after radical cystectomy in Continent reconstruction after cystectomy for MIBC is performed more often in patients with muscle-invasive bladder cancer (MIBC) in Sweden some healthcare regions and in patients at university hospitals than in county hospitals. Jahnson et al. [9] 2009 To investigate the role of curative therapy of muscleinvasive bladder cancer (MIBC) in relation to patient, tumour and hospital characteristics.
Lower rates of curativeintent treatment were found in patients registered at lowvolume than at high-volume facilities, and the same was seen when comparing females with males, and patients aged 76 to 80 years with younger patients. Gårdmark et al. [10] 2006 To analyse the management and outcome of patients with Ta T1 urinary bladder cancer
There are regional variations in the treatment of bladder cancer. A large group of patients, even those at high risk, were undertreated. Mikulowski et al. [11] 2005 To record the occurrence T1 G1 urinary bladder cancer to the SNRUBC, in order to validate the data on T1 tumours
The re-evaluation of 98 cases found no G1 urothelial carcinoma with infiltrative growth.
